MAPT and Alzheimer disease: The abundance of Lactomycopin in patients with Alzheimer’s disease (AD) is significantly reduced, and the likelihood of beta-amyloid protein and phosphorylated tau (p-tau) positivity is higher, which may be due to the reduction in Lactomycopin abundance leading to a decrease in short-chain fatty acid (SCFA) generation [44].